Valeant stock surged as much as 6% Tuesday on the news. Take Dendreon, which makes cancer immunotherapy treatment Provenge, …
Valeant
Selling the Dendreon business will help Valeant simplify and focus on ... Register now to create your own custom streaming stock watchlist. …
Valeant
Basically, if Valeant would have sold Dendreon in May of last year for the same $820 million ... I have no business relationship with any company whose stock is mentioned in this article.
Valeant
It would seem that Valeant, which has seen its stock price rise around 9% in 30 days ... Valeant said it entered into an agreement to sell all the outstanding equity interest in Dendreon Pharmaceuticals to the China-based …
short sellers
Valeant had bought Dendreon two years ago for $400 million ...
asset sales
Dendreon (DNDN) stock opened slightly higher this morning, despite the fact that Dendreon earnings for Q3 rolled in even worse than expected. Product revenue for DNDN — which is to say revenue from its only …
The seemingly endless stream of bad news caused the stock to tumble more than 85% in 2016; however, management's news today could …
Valeant Pharmaceuticals
Merck is a Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks ... The other agreement will see Valeant selling off the outstanding equity interests in Dendreon Pharmaceuticals to the Sanpower …
Merck
Beleaguered Valeant Pharmaceuticals International, Inc. (VRX - Free Report) announced that its affiliate has entered into a definitive agreement to sell all the outstanding equity interests in Dendreon Pharmaceuticals, …
Valeant